Characteristics | Overall survival | Progression-free survival | ||
---|---|---|---|---|
training cohort(n = 180) | validation cohort(n = 120) | training cohort(n = 180) | validation cohort(n = 120) | |
TNM stage | 0.700(0.601–0.799) | 0.608(0.512–0.704) | 0.699(0.616–0.782) | 0.606(0.469–0.607) |
SSIGN | 0.647(0.549–0.745) | 0.608(0.511–0.705) | 0.684(0.598–0.770) | 0.624(0.536–0.728) |
HECW1 | 0.825(0.790–0.860) | 0.807(0.755–0.859) | 0.791(0.749–0.833) | 0.828(0.786–0.874) |
HECW1 + TNM | 0.876(0.833–0.919) | 0.822(0.768–0.876) | 0.842(0.796–0.888) | 0.836(0.761–0.863) |
HECW1 + SSIGN | 0.870(0.825–0.915) | 0.830(0.771–0.889) | 0.854(0.803–0.905) | 0.857(0.817–0.911) |